Literature DB >> 25124472

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.

Joseph H Helm1, John T Miura, Jason A Glenn, Rebecca K Marcus, Gregory Larrieux, Thejus T Jayakrishnan, Amy E Donahue, T Clark Gamblin, Kiran K Turaga, Fabian M Johnston.   

Abstract

BACKGROUND: Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature.
METHODS: The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots.
RESULTS: Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49-55), with 59 % (54-67) female. The median peritoneal carcinomatosis index score was 19 (16-23). Complete cytoreduction (CC0, 1) was performed in 67 % (46-93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival.
CONCLUSIONS: While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

Entities:  

Mesh:

Year:  2014        PMID: 25124472     DOI: 10.1245/s10434-014-3978-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  49 in total

1.  Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma.

Authors:  Marije Wijnberge; Lidewine Daniels; Vincent Cliteur; Jasper Winkelhagen
Journal:  BMJ Case Rep       Date:  2017-03-06

2.  The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking.

Authors:  Samer A Naffouje; Kiara A Tulla; George I Salti
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

Review 3.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

4.  Global Forum of Cancer Surgeons: Support for the Brazilian Society of Surgical Oncology Journey towards Implementation of Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy in Brazil.

Authors:  Alexandre Ferreira Oliveira; Claudio Almeida Quadros; Héber Salvador de Castro Ribeiro; Alberto Julius Alves Wainstein; Bruno José de Queiroz Sarmento; Jorge Lyra; Glauco Baiocchi Neto; Reitan Ribeiro; Rodrigo Nascimento Pinheiro; Elio José Silveira da Silva Barreto; Jason Park; Andrew McKay; Arnab Gupta; Dhairyasheel Savant; Aviram Nissan; Douglas Zippel; Augusto Leon; Juan Enrique Bargallo-Rocha; Hector Martinez Said; Yuko Kitagawa; Kazuhiro Yoshida; Woo Yong Lee; Do Joong Park; Ashraf Zaghloul; Wael A Gawad; Gong Chen; Haroon Javaid Majid; Muhammad Arshad Cheema; Alessandro Gronchi; Tibor Kovacs; Domenico D'Ugo; David L Bartlett; James R Howe; Chandrakanth Are
Journal:  Ann Surg Oncol       Date:  2021-01-18       Impact factor: 5.344

5.  Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.

Authors:  David B Chapel; Jefree J Schulte; Gudrun Absenger; Richard Attanoos; Luka Brcic; Kelly J Butnor; Lucian Chirieac; Andrew Churg; Françoise Galateau-Sallé; Kenzo Hiroshima; Yin P Hung; Hedy Kindler; Thomas Krausz; Alberto Marchevsky; Mari Mino-Kenudson; Jeffrey Mueller; Kazuki Nabeshima; Kirin Turaga; Ann E Walts; Aliya N Husain
Journal:  Mod Pathol       Date:  2020-10-15       Impact factor: 7.842

Review 6.  Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis.

Authors:  Paul H Sugarbaker; David Chang
Journal:  Ann Surg Oncol       Date:  2021-05-03       Impact factor: 5.344

7.  Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database.

Authors:  Lana Bijelic; Kathleen Darcy; Joshua Stodghill; Chunqiao Tian; Timothy Cannon
Journal:  Ann Surg Oncol       Date:  2020-01-31       Impact factor: 5.344

Review 8.  Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies.

Authors:  Yan Li; Yun-Feng Zhou; Han Liang; Hua-Qing Wang; Ji-Hui Hao; Zheng-Gang Zhu; De-Seng Wan; Lun-Xiu Qin; Shu-Zhong Cui; Jia-Fu Ji; Hui-Mian Xu; Shao-Zhong Wei; Hong-Bin Xu; Tao Suo; Shu-Jun Yang; Cong-Hua Xie; Xiao-Jun Yang; Guo-Liang Yang
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 9.  Malignant peritoneal mesothelioma: a review.

Authors:  Glenn Broeckx; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 10.  Update on the management of malignant peritoneal mesothelioma.

Authors:  Paul H Sugarbaker
Journal:  Transl Lung Cancer Res       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.